Back to Journals » Infection and Drug Resistance » Volume 13

Blood Neutrophil-to-Lymphocyte Ratio and Urine IL-8 Levels Predict the Type of Bacterial Urinary Tract Infection in Type 2 Diabetes Mellitus Patients

Authors Saheb Sharif-Askari F, Saheb Sharif-Askari N, Guella A, Alabdullah A, Bashar Al Sheleh H, Maher Hoory AlRawi A, Sami Haddad E, Hamid Q, Halwani R, Hamoudi R

Received 1 March 2020

Accepted for publication 26 May 2020

Published 24 June 2020 Volume 2020:13 Pages 1961—1970

DOI https://doi.org/10.2147/IDR.S251966

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Suresh Antony


Fatemeh Saheb Sharif-Askari,1 Narjes Saheb Sharif-Askari,1 Adnane Guella,2 Ali Alabdullah,1,* Hour Bashar Al Sheleh,1,* Afnan Maher Hoory AlRawi,1,* Enad Sami Haddad,1,* Qutayba Hamid,1,3 Rabih Halwani,1,3,4 Rifat Hamoudi1,3

1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; 2Department of Nephrology, University Hospital Sharjah, Sharjah, United Arab Emirates; 3Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; 4Prince Abdullah Ben Khaled Celiac Disease Research Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia

*These authors contributed equally to this work

Correspondence: Rifat Hamoudi; Rabih Halwani
College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
Email rhamoudi@sharjah.ac.ae; rhalwani@sharjah.ac.ae

Background: Extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) are the most common uropathogens causing UTI (urinary tract infection) in type 2 diabetes mellitus (T2DM). Circulatory inflammatory markers such as C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) are usually dysregulated during UTI. However, the differential regulation of these inflammatory signatures during E. coli and K. pneumoniae UTI in T2DM has not been determined.
Methods: A case–control study on 466 patients was performed to investigate the inflammatory signatures indicative of ESBL-E. coli and K. pneumoniae UTIs in T2DM. Serum CRP levels and blood NLR for these patients were determined and associated with E. coli and K. pneumoniae ESBL uropathogen using multivariate logistic regression analysis. Urinary interleukin 8 (IL-8) levels were also assessed and associated with these two UTI uropathogens in T2DM. The association of the two ESBL-uropathogens with the survival outcomes of T2DM patients was also analyzed using Cox-proportional hazard model.
Results: T2DM patients with ESBL-E. coli UTI had lower serum CRP levels (median, CRP mg/dL 33.7 vs 39.8, respectively; P=0.023) and higher blood NLR (median, NLR 3.2 vs 2.6, respectively; P=0.010) compared to those with K. pneumoniae UTIs (P< 0.001). Moreover, in T2DM, the urinary IL-8 levels was higher in ESBL-E. coli compared to those with K. pneumoniae UTIs (P< 0.0001). After adjusting for confounders, including age, gender, serum albumin, hemoglobulin, leukocytes, and platelet counts, T2DM patients with blood NLR ≥ 3.5 were at higher risk for ESBL-E. coli UTIs than ESBL-K. pneumoniae UTIs (odds ratio [OR], 3.61, 95% confidence interval, Cl, 1.49– 8.73; P=0.004). Moreover, T2DM patients with ESBL-E. coli UTIs had higher all-cause mortality (hazard ratio [HR], 4.09; 95%, 1.14– 14.59) than those with K. pneumoniae UTIs.
Conclusion: Serum CRP levels, blood NLR, and IL-8 urinary levels differentiate ESBL-E. coli from K. pneumoniae UTIs in T2DM.

Keywords: extended-spectrum ß-lactamase, Klebsiella pneumoniae, Escherichia coli, urinary tract infection, C-reactive protein, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]